Denali Therapeutics (DNLI) Financials

$15.99 -0.45 (-2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$16.01 +0.02 (+0.13%)

As of 06:08 PM Eastern

Annual Income Statements for Denali Therapeutics

This table shows Denali Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-87	-88	-37	-197	71	-293	-330	-138	-421
Consolidated Net Income / (Loss)	-87	-88	-36	-198	71	-291	-326	-145	-423
Net Income / (Loss) Continuing Operations	-87	-88	-36	-198	71	-291	-326	-145	-423
Total Pre-Tax Income	-87	-88	-46	-213	63	-296	-326	-145	-423
Total Operating Income	-87	-90	-46	-213	63	-296	-341	-197	-487
Total Gross Profit	0.00	0.00	129	27	336	49	108	331	0.00
Total Revenue	0.00	0.00	129	27	336	49	108	331	0.00
Operating Revenue	0.00	0.00	129	27	336	49	108	331	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	87	90	176	240	273	344	449	527	487
Selling, General & Admin Expense	12	16	32	46	60	79	90	103	105
Research & Development Expense	76	74	143	193	213	265	359	424	396
Other Special Charges / (Income)	-	-	-	-	-	-	-	0.00	-15
Total Other Income / (Expense), net	0.00	1.96	0.00	0.00	0.00	0.00	15	52	65
Interest & Investment Income	-	-	-	-	-	-	15	52	65
Income Tax Expense	-	0.00	0.00	-0.35	0.82	-0.58	0.02	0.03	0.07
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.37	-0.01	0.28	-1.00	0.60	2.25	4.39	-7.53	-1.38
Basic Earnings per Share	($13.49)	($5.89)	($0.39)	($2.07)	$0.65	($2.39)	($2.60)	($1.06)	($2.57)
Weighted Average Basic Shares Outstanding	6.42M	14.96M	92.62M	95.61M	108.97M	121.52M	125.53M	137.37M	164.47M
Diluted Earnings per Share	($13.49)	($5.89)	($0.39)	($2.07)	$0.63	($2.39)	($2.60)	($1.06)	($2.57)
Weighted Average Diluted Shares Outstanding	6.42M	14.96M	92.62M	95.61M	112.70M	121.52M	125.53M	137.37M	164.47M
Weighted Average Basic & Diluted Shares Outstanding	6.42M	14.96M	92.62M	95.61M	108.97M	122.83M	136.68M	139.16M	145.22M

This table shows Denali Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-103	-94	-105	184	-99	-118	-104	-100	-99	-118
Consolidated Net Income / (Loss)	-103	-99	-110	183	-99	-119	-102	-99	-107	-115
Net Income / (Loss) Continuing Operations	-103	-99	-110	183	-99	-119	-102	-99	-107	-115
Total Pre-Tax Income	-103	-95	-110	183	-99	-119	-102	-99	-107	-115
Total Operating Income	-107	-105	-121	170	-114	-133	-118	-117	-123	-130
Total Operating Expenses	111	116	156	124	115	133	118	117	123	130
Selling, General & Admin Expense	23	24	27	26	25	25	25	25	25	30
Research & Development Expense	88	92	129	98	90	108	107	91	98	100
Total Other Income / (Expense), net	4.19	11	11	13	14	13	16	18	16	15
Interest & Investment Income	-	-	11	13	14	13	16	18	16	15
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.42	-4.97	-4.37	-1.08	-0.79	-1.29	1.94	1.36	-8.19	3.51
Basic Earnings per Share	($0.84)	($0.75)	($0.80)	$1.34	($0.72)	($0.88)	($0.68)	($0.59)	($0.63)	($0.67)
Weighted Average Basic Shares Outstanding	123.47M	125.53M	136.52M	137.05M	137.64M	137.37M	149.40M	168.83M	169.46M	164.47M
Diluted Earnings per Share	($0.84)	($0.75)	($0.80)	$1.30	($0.72)	($0.84)	($0.68)	($0.59)	($0.63)	($0.67)
Weighted Average Diluted Shares Outstanding	123.47M	125.53M	136.52M	140.93M	137.64M	137.37M	149.40M	168.83M	169.46M	164.47M
Weighted Average Basic & Diluted Shares Outstanding	135.81M	136.68M	136.89M	137.42M	138.20M	139.16M	142.61M	143.17M	143.92M	145.22M

This table details how cash moves in and out of Denali Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	9.56	179	-140	2.33	428	-214	-75	-91	48
Net Cash From Operating Activities	-72	-77	50	-152	416	-211	-245	-358	-348
Net Cash From Continuing Operating Activities	-72	-77	50	-152	416	-211	-245	-358	-348
Net Income / (Loss) Continuing Operations	-87	-88	-36	-198	71	-291	-326	-145	-423
Consolidated Net Income / (Loss)	-87	-88	-36	-198	71	-291	-326	-145	-423
Depreciation Expense	1.47	3.08	7.42	7.99	8.53	8.59	10	17	7.80
Amortization Expense	0.30	0.75	-2.71	-5.02	0.06	8.75	0.00	-44	1.20
Non-Cash Adjustments To Reconcile Net Income	8.23	4.41	19	40	48	82	64	104	49
Changes in Operating Assets and Liabilities, net	4.74	3.31	63	2.92	288	-20	7.28	-290	17
Net Cash From Investing Activities	-219	-41	-287	148	-623	-22	-141	249	-89
Net Cash From Continuing Investing Activities	-219	-41	-287	148	-623	-22	-141	249	-89
Purchase of Property, Plant & Equipment	-6.13	-2.88	-3.39	-18	-3.10	-8.50	-18	-13	-16
Purchase of Investments	-227	-180	-558	-370	-1,285	-1,423	-1,115	-1,814	-1,230
Sale and/or Maturity of Investments	14	141	274	535	665	1,410	991	2,076	1,157
Net Cash From Financing Activities	300	296	97	6.19	635	19	311	18	484
Net Cash From Continuing Financing Activities	300	296	97	6.19	635	19	311	18	484
Issuance of Common Equity	0.00	266	94	0.00	614	19	311	18	517
Other Financing Activities, net	0.11	0.73	4.00	6.19	21	-	0.00	0.00	-32
Cash Interest Paid	-	-	-	-	-	-	0.00	0.00	0.30
Cash Income Taxes Paid	-	-	-	-	0.00	0.21	0.05	0.00	0.00

This table details how cash moves in and out of Denali Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-36	99	-150	64	16	-21	-67	14	16	84
Net Cash From Operating Activities	-57	-73	-59	-113	-87	-99	-114	-91	-59	-84
Net Cash From Continuing Operating Activities	-57	-73	-59	-113	-87	-99	-114	-91	-59	-84
Net Income / (Loss) Continuing Operations	-103	-99	-110	183	-99	-119	-102	-99	-107	-115
Consolidated Net Income / (Loss)	-103	-99	-110	183	-99	-119	-102	-99	-107	-115
Depreciation Expense	2.14	4.09	10	2.29	2.22	2.18	2.16	1.94	1.84	1.85
Amortization Expense	-0.69	-1.43	-7.85	-12	19	-44	-11	-10	21	0.77
Non-Cash Adjustments To Reconcile Net Income	24	-8.61	27	26	-5.21	57	12	24	-5.14	18
Changes in Operating Assets and Liabilities, net	21	32	22	-313	-4.41	5.85	-16	-8.16	30	11
Net Cash From Investing Activities	15	-128	-93	168	101	73	-453	99	94	172
Net Cash From Continuing Investing Activities	15	-128	-93	168	101	73	-453	99	94	172
Purchase of Property, Plant & Equipment	-6.05	-4.85	-2.79	-5.85	-2.07	-2.24	-2.15	-4.79	-3.88	-5.09
Purchase of Investments	-123	-487	-524	-378	-498	-414	-834	-122	-100	-174
Sale and/or Maturity of Investments	144	364	434	552	601	489	383	225	198	351
Net Cash From Financing Activities	5.15	300	1.60	9.02	2.49	4.71	500	6.76	-19	-4.17
Net Cash From Continuing Financing Activities	5.15	300	1.60	9.02	2.49	4.71	500	6.76	-19	-4.17
Issuance of Common Equity	5.15	300	1.60	9.02	2.49	4.71	500	6.76	5.46	4.16
Other Financing Activities, net	-	-	-	-	-	-	-	-	-	-8.32
Cash Interest Paid	-	-	-	-	-	-	-	-	-	0.18

This table presents Denali Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	487	662	553	1,604	1,404	1,460	1,154	1,374
Total Current Assets	410	481	430	1,496	897	1,372	1,064	864
Cash & Equivalents	218	77	79	507	293	218	127	175
Short-Term Investments	188	387	336	963	572	1,118	907	657
Prepaid Expenses	3.38	17	15	20	31	36	30	32
Plant, Property, & Equipment, net	15	25	47	41	39	44	46	55
Total Noncurrent Assets	62	156	76	68	468	44	44	455
Long-Term Investments	61	148	40	33	425	-	0.00	359
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	0.00	48
Other Noncurrent Operating Assets	1.44	8.11	37	35	43	44	44	48
Total Liabilities & Shareholders' Equity	487	662	553	1,604	1,404	1,460	1,154	1,374
Total Liabilities	21	115	158	454	442	418	123	144
Total Current Liabilities	14	33	45	72	378	364	78	102
Accounts Payable	2.72	1.89	2.59	1.07	4.78	2.79	9.48	11
Accrued Expenses	5.36	-	-	-	-	67	68	91
Total Noncurrent Liabilities	6.76	82	113	382	64	54	45	42
Other Noncurrent Operating Liabilities	0.47	58	113	382	64	53	45	42
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	466	547	395	1,151	962	1,042	1,031	1,230
Total Preferred & Common Equity	466	547	395	1,151	962	1,042	1,031	1,230
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	466	547	395	1,151	962	1,042	1,031	1,230
Common Stock	658	775	820	1,505	1,610	2,020	2,147	2,767
Retained Earnings	-192	-228	-426	-354	-645	-971	-1,116	-1,539
Accumulated Other Comprehensive Income / (Loss)	-0.37	-0.65	0.35	-0.25	-2.50	-6.89	0.64	2.02

This table presents Denali Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,228	1,409	1,306	1,237	1,581	1,503	1,454
Total Current Assets	1,139	1,325	1,224	1,143	974	928	869
Cash & Equivalents	119	68	132	148	61	75	91
Short-Term Investments	987	1,220	1,059	961	876	821	746
Prepaid Expenses	32	37	33	34	37	32	32
Plant, Property, & Equipment, net	42	42	40	48	47	48	51
Total Noncurrent Assets	47	42	42	46	561	526	534
Long-Term Investments	0.00	-	-	7.91	491	451	445
Noncurrent Note & Lease Receivables	-	-	-	-	-	-	39
Other Noncurrent Operating Assets	47	42	42	38	70	75	50
Total Liabilities & Shareholders' Equity	1,228	1,409	1,306	1,237	1,581	1,503	1,454
Total Liabilities	416	443	119	118	126	116	136
Total Current Liabilities	361	391	69	71	83	75	87
Accounts Payable	8.98	11	15	12	12	14	9.59
Accrued Expenses	41	77	36	36	43	33	38
Current Deferred Revenue	-	-	-	-	13	10	16
Current Employee Benefit Liabilities	13	7.37	10	16	8.05	9.56	15
Other Current Liabilities	298	296	7.62	7.01	7.51	7.77	8.04
Total Noncurrent Liabilities	56	52	50	47	43	41	48
Other Noncurrent Operating Liabilities	56	52	50	47	43	41	48
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	811	967	1,187	1,118	1,455	1,387	1,318
Total Preferred & Common Equity	811	967	1,187	1,118	1,455	1,387	1,318
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	811	967	1,187	1,118	1,455	1,387	1,318
Common Stock	1,695	2,050	2,086	2,116	2,675	2,707	2,737
Retained Earnings	-872	-1,081	-897	-997	-1,218	-1,317	-1,424
Accumulated Other Comprehensive Income / (Loss)	-12	-2.52	-1.44	-0.65	-1.30	-2.66	5.53

This table displays calculated financial ratios and metrics derived from Denali Therapeutics' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	-79.35%	1,158.19%	-85.50%	122.90%	204.74%	-100.00%
EBITDA Growth	0.00%	1.53%	50.61%	-404.57%	133.92%	-490.46%	-18.66%	32.22%	-113.62%
EBIT Growth	0.00%	-0.86%	47.42%	-359.73%	129.42%	-571.56%	-15.21%	42.27%	-147.76%
NOPAT Growth	0.00%	-3.10%	48.56%	-359.73%	141.48%	-434.48%	-15.21%	42.27%	-147.76%
Net Income Growth	0.00%	-1.77%	58.90%	-445.29%	136.00%	-508.49%	-12.19%	55.45%	-191.12%
EPS Growth	0.00%	56.34%	93.38%	-430.77%	130.43%	-479.37%	-8.79%	59.23%	-142.45%
Operating Cash Flow Growth	0.00%	-6.57%	165.40%	-402.45%	374.55%	-150.80%	-15.77%	-46.29%	2.88%
Free Cash Flow Firm Growth	0.00%	0.00%	151.18%	-586.58%	329.17%	-165.17%	-18.66%	-56.57%	10.57%
Invested Capital Growth	0.00%	0.00%	-5,436.69%	7.62%	-483.02%	6.62%	10.59%	98.79%	1,167.75%
Revenue Q/Q Growth	0.00%	0.00%	3,607.23%	-81.94%	1,327.36%	-86.21%	-2.02%	-3.02%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	70.41%	-172.08%	130.64%	-770.66%	-10.02%	-45.50%	8.97%
EBIT Q/Q Growth	0.00%	0.00%	67.94%	-164.16%	126.23%	-1,262.18%	-9.03%	-16.07%	0.56%
NOPAT Q/Q Growth	0.00%	0.00%	67.94%	-84.91%	136.98%	-913.52%	-9.03%	-16.07%	0.56%
Net Income Q/Q Growth	0.00%	0.00%	84.02%	-922.06%	131.23%	-1,082.85%	-7.74%	-16.71%	1.10%
EPS Q/Q Growth	0.00%	0.00%	-18.18%	-213.64%	128.38%	-568.63%	-5.26%	-9.28%	6.20%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	181.62%	-1,310.27%	386.20%	-157.44%	-3.02%	-7.83%	4.12%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-114.39%	365.49%	-184.42%	-1.08%	-3.22%	-1.14%
Invested Capital Q/Q Growth	0.00%	0.00%	-16.77%	6.76%	-255.45%	5.14%	0.33%	-404.02%	4.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
EBITDA Margin	0.00%	0.00%	-32.26%	-787.96%	21.24%	-572.14%	-304.58%	-67.75%	0.00%
Operating Margin	0.00%	0.00%	-35.90%	-799.10%	18.69%	-607.78%	-314.16%	-59.51%	0.00%
EBIT Margin	0.00%	0.00%	-35.90%	-799.10%	18.69%	-607.78%	-314.16%	-59.51%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	-28.06%	-740.74%	21.19%	-597.15%	-300.56%	-43.94%	0.00%
Tax Burden Percent	99.11%	100.00%	78.15%	92.70%	113.42%	98.25%	100.01%	100.02%	100.02%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	95.66%	73.82%	86.74%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	1.31%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-18.93%	-7.16%	-41.97%	9.21%	-27.51%	-32.52%	-14.01%	-37.40%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,007.57%
Operating Return on Assets (OROA)	0.00%	0.00%	-8.07%	-35.09%	5.81%	-19.66%	-23.79%	-15.05%	0.00%
Return on Assets (ROA)	0.00%	0.00%	-6.31%	-32.52%	6.59%	-19.32%	-22.76%	-11.11%	0.00%
Return on Common Equity (ROCE)	0.00%	-18.93%	-7.16%	-41.97%	9.21%	-27.51%	-32.52%	-14.01%	-37.40%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-18.93%	-6.63%	-50.04%	6.18%	-30.20%	-31.27%	-14.09%	-34.38%
Net Operating Profit after Tax (NOPAT)	-61	-63	-32	-149	62	-207	-239	-138	-341
NOPAT Margin	0.00%	0.00%	-25.13%	-559.37%	18.44%	-425.44%	-219.91%	-41.66%	0.00%
Net Nonoperating Expense Percent (NNEP)	0.00%	-10.74%	-0.70%	-9.07%	0.94%	-5.98%	-6.66%	-0.64%	-7.33%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-22.88%	-13.36%	-27.74%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	25.05%	174.23%	17.97%	162.47%	83.42%	31.27%	0.00%
R&D to Revenue	0.00%	0.00%	110.86%	724.87%	63.34%	545.31%	330.74%	128.24%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	135.90%	899.10%	81.32%	707.78%	414.16%	159.51%	0.00%
Earnings before Interest and Taxes (EBIT)	-87	-88	-46	-213	63	-296	-341	-197	-487
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-86	-84	-42	-210	71	-278	-330	-224	-478
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	3.59	4.24	8.73	5.66	3.62	2.88	2.39
Price to Tangible Book Value (P/TBV)	0.00	0.00	3.59	4.24	8.73	5.66	3.62	2.88	2.39
Price to Revenue (P/Rev)	0.00	0.00	15.19	62.71	29.92	111.93	34.82	8.97	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	142.39	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.70%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	45.85
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	10.45	45.64	25.45	85.41	22.50	5.84	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	119.80	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	136.20	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	138.01	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	26.93	0.00	20.53	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	42.59	0.00	24.17	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.00	-1.07	-1.13	-1.27	-1.32	-1.31	-1.14	-0.98
Leverage Ratio	0.00	1.04	1.13	1.29	1.40	1.42	1.43	1.26	1.12
Compound Leverage Factor	0.00	1.04	1.13	1.29	1.40	1.42	1.37	0.93	0.97
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	10.52	4.87	14.38	6.54	4.63	13.87	10.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	28.92	14.67	9.48	20.86	2.37	3.77	13.65	8.46
Quick Ratio	0.00	28.68	14.16	9.16	20.58	2.29	3.67	13.27	8.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-62	32	-154	353	-230	-273	-428	-383
Operating Cash Flow to CapEx	-1,172.29%	-2,665.57%	1,477.04%	-845.90%	13,445.95%	-2,486.93%	-1,372.26%	-2,766.76%	-2,185.11%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.22	0.04	0.31	0.03	0.08	0.25	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	14.10	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	6.44	0.74	7.67	1.22	2.62	7.37	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	25.88	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	25.88	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-1.18	-65	-60	-352	-329	-294	-3.56	38
Invested Capital Turnover	0.00	0.00	-3.88	-0.42	-1.63	-0.14	-0.35	-2.22	0.00
Increase / (Decrease) in Invested Capital	0.00	-1.18	-64	4.98	-292	23	35	290	42
Enterprise Value (EV)	0.00	0.00	1,350	1,218	8,542	4,156	2,441	1,931	1,741
Market Capitalization	0.00	0.00	1,962	1,673	10,044	5,447	3,777	2,966	2,933
Book Value per Share	$0.00	$31.13	$5.76	$4.11	$9.59	$7.88	$7.68	$7.46	$8.54
Tangible Book Value per Share	$0.00	$31.13	$5.76	$4.11	$9.59	$7.88	$7.68	$7.46	$8.54
Total Capital	0.00	466	547	395	1,151	962	1,042	1,031	1,230
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-467	-612	-455	-1,502	-1,291	-1,336	-1,035	-1,192
Capital Expenditures (CapEx)	6.13	2.88	3.39	18	3.10	8.50	18	13	16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-11	-16	-31	-46	-346	-328	-48	-70
Debt-free Net Working Capital (DFNWC)	0.00	395	448	385	1,424	519	1,008	986	762
Net Working Capital (NWC)	0.00	395	448	385	1,424	519	1,008	986	762
Net Nonoperating Expense (NNE)	25	25	3.78	48	-9.24	84	87	7.53	82
Net Nonoperating Obligations (NNO)	0.00	-467	-612	-455	-1,502	-1,291	-1,336	-1,035	-1,192
Total Depreciation and Amortization (D&A)	1.77	3.84	4.71	2.97	8.59	17	10	-27	8.99
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-12.58%	-114.96%	-13.63%	-711.90%	-302.24%	-14.63%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	346.90%	1,441.96%	424.23%	1,066.54%	929.72%	298.35%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	346.90%	1,441.96%	424.23%	1,066.54%	929.72%	298.35%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.39)	($2.07)	$0.65	($2.39)	($2.60)	($1.06)	($2.57)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	95.29M	105.42M	108.97M	121.52M	125.53M	137.37M	164.47M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.39)	($2.07)	$0.63	($2.39)	($2.60)	($1.06)	($2.57)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	95.29M	105.42M	108.97M	121.52M	125.53M	137.37M	164.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($0.39)	($2.07)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	92.62M	95.61M	108.97M	122.83M	136.68M	139.16M	145.22M
Normalized Net Operating Profit after Tax (NOPAT)	-61	-63	-32	-149	62	-207	-239	-138	-351
Normalized NOPAT Margin	0.00%	0.00%	-25.13%	-559.37%	18.44%	-425.44%	-219.91%	-41.66%	0.00%
Pre Tax Income Margin	0.00%	0.00%	-35.90%	-799.10%	18.69%	-607.78%	-300.54%	-43.93%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-3.82%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Denali Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-32.66%	-17.83%	-16.61%	460.45%	-64.40%	0.00%	-100.00%	-100.00%	-100.00%	0.00%
EBITDA Growth	-26.13%	-41.45%	-88.91%	373.96%	9.48%	-69.79%	-6.28%	-177.35%	-8.84%	27.03%
EBIT Growth	-20.69%	-36.60%	-81.68%	377.59%	-10.16%	-25.85%	2.57%	-168.39%	-8.25%	2.06%
NOPAT Growth	-25.58%	-36.60%	-81.68%	496.55%	-5.87%	-25.85%	2.57%	-147.87%	-8.25%	2.06%
Net Income Growth	-22.12%	-31.11%	-68.32%	411.91%	3.82%	-21.07%	7.27%	-154.00%	-7.89%	3.95%
EPS Growth	-21.74%	-20.97%	-50.94%	370.83%	14.29%	-12.00%	15.00%	-145.38%	12.50%	20.24%
Operating Cash Flow Growth	-37.68%	-10.95%	18.45%	-163.81%	-53.14%	-35.77%	-93.22%	19.39%	32.31%	15.15%
Free Cash Flow Firm Growth	-167.67%	-40.42%	49.03%	-11.25%	-196.06%	-252.95%	-720.00%	-21.19%	67.64%	65.43%
Invested Capital Growth	14.90%	10.59%	-11.00%	98.51%	100.40%	98.79%	108.67%	1,061.39%	3,017.35%	1,167.75%
Revenue Q/Q Growth	-93.22%	188.93%	241.74%	736.98%	-99.57%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-73.05%	-0.82%	-13.71%	235.92%	-157.18%	-89.11%	11.62%	1.08%	19.54%	-26.79%
EBIT Q/Q Growth	-68.20%	-1.98%	-14.69%	241.11%	-166.75%	-16.50%	11.21%	0.95%	-5.66%	-5.41%
NOPAT Q/Q Growth	-75.01%	1.99%	-14.69%	301.59%	-146.72%	-16.50%	11.21%	0.95%	-5.66%	-5.41%
Net Income Q/Q Growth	-75.70%	4.47%	-11.25%	267.04%	-154.18%	-20.25%	14.79%	2.73%	-8.25%	-7.05%
EPS Q/Q Growth	-75.00%	10.71%	-6.67%	262.50%	-155.38%	-16.67%	19.05%	13.24%	-6.78%	-6.35%
Operating Cash Flow Q/Q Growth	-32.98%	-27.38%	19.08%	-92.46%	22.80%	-12.93%	-15.17%	19.71%	35.17%	-41.56%
Free Cash Flow Firm Q/Q Growth	-35.97%	14.46%	51.45%	-97.00%	-261.85%	-1.98%	-12.79%	70.88%	3.38%	-8.96%
Invested Capital Q/Q Growth	-5.86%	0.33%	-9.52%	98.71%	128.11%	-404.02%	883.89%	43.50%	-8.85%	4.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-2,861.65%	-998.57%	-337.56%	54.82%	-7,276.40%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-3,020.12%	-1,024.45%	-343.80%	57.96%	-8,981.45%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-2,902.47%	-1,024.45%	-343.80%	57.96%	-8,981.45%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-2,902.47%	-959.62%	-312.40%	62.35%	-7,841.59%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	104.14%	100.00%	100.00%	100.00%	100.03%	100.00%	100.00%	100.00%	100.06%
Interest Burden Percent	100.00%	89.95%	90.87%	107.57%	87.31%	90.10%	86.48%	84.93%	87.02%	88.32%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-33.18%	-32.52%	-39.32%	-12.40%	-12.90%	-14.01%	-11.33%	0.00%	-35.09%	-37.40%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	-35,431.77%	0.00%	-1,739.95%	-951.31%	-2,010.20%	-1,007.57%
Operating Return on Assets (OROA)	-239.98%	-77.58%	-25.55%	15.31%	-2,484.20%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-239.98%	-72.67%	-23.22%	16.47%	-2,168.92%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-33.18%	-32.52%	-39.32%	-12.40%	-12.90%	-14.01%	-11.33%	0.00%	-35.09%	-37.40%
Return on Equity Simple (ROE_SIMPLE)	-37.29%	0.00%	-38.33%	-10.82%	-11.13%	0.00%	-9.43%	-30.26%	-32.42%	0.00%
Net Operating Profit after Tax (NOPAT)	-75	-74	-85	170	-80	-93	-82	-82	-86	-91
NOPAT Margin	-2,114.08%	-717.11%	-240.66%	57.96%	-6,287.02%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-2.28%	-1.90%	-2.02%	1.10%	-1.77%	-2.25%	-1.43%	-1.37%	-1.75%	-2.14%
Return On Investment Capital (ROIC_SIMPLE)	-	-7.07%	-	-	-	-9.00%	-	-	-	-7.39%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	653.53%	228.69%	77.23%	8.88%	1,998.82%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	2,466.59%	895.76%	366.57%	33.16%	7,082.64%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	3,120.12%	1,124.45%	443.80%	42.04%	9,081.45%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-103	-105	-121	170	-114	-133	-118	-117	-123	-130
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-102	-103	-119	161	-92	-174	-126	-125	-100	-127
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.67	3.62	3.26	3.40	2.54	2.88	1.95	2.39	3.16	2.39
Price to Tangible Book Value (P/TBV)	4.67	3.62	3.26	3.40	2.54	2.88	1.95	2.39	3.16	2.39
Price to Revenue (P/Rev)	34.20	34.82	31.04	11.77	8.32	8.97	9.60	2,613.56	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	1,468.25	0.00	50.50	49.09	79.19	45.85
Enterprise Value to Revenue (EV/Rev)	24.21	22.50	18.34	8.30	5.04	5.84	4.77	1,550.39	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.35	-1.31	-1.32	-1.14	-1.15	-1.14	-1.12	-0.99	-0.98	-0.98
Leverage Ratio	1.47	1.43	1.45	1.25	1.28	1.26	1.23	1.09	1.10	1.12
Compound Leverage Factor	1.47	1.29	1.32	1.35	1.12	1.14	1.07	0.93	0.96	0.99
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.03	5.16	3.78	21.18	14.24	14.05	13.08	16.40	17.46	10.97
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.16	3.77	3.39	17.65	16.06	13.65	11.79	12.46	9.98	8.46
Quick Ratio	3.07	3.67	3.29	17.17	15.58	13.27	11.34	12.02	9.61	8.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-127	-109	-53	-104	-376	-383	-432	-126	-122	-132
Operating Cash Flow to CapEx	-942.91%	-1,498.52%	-2,110.62%	-1,934.51%	-4,224.52%	-4,414.18%	-5,284.65%	-1,905.98%	-1,522.63%	-1,644.05%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.08	0.08	0.07	0.26	0.28	0.25	0.20	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	2.71	2.62	2.54	8.74	7.59	7.37	6.64	0.03	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-295	-294	-322	-4.16	1.17	-3.56	28	40	36	38
Invested Capital Turnover	-0.35	-0.35	-0.33	-2.43	-2.32	-2.22	-2.01	0.07	0.00	0.00
Increase / (Decrease) in Invested Capital	52	35	-32	274	296	290	350	44	35	42
Enterprise Value (EV)	2,680	2,441	1,861	2,849	1,718	1,931	1,408	1,964	2,888	1,741
Market Capitalization	3,786	3,777	3,149	4,040	2,835	2,966	2,836	3,311	4,170	2,933
Book Value per Share	$6.58	$7.68	$7.07	$8.67	$8.14	$7.46	$9.74	$9.73	$9.21	$8.54
Tangible Book Value per Share	$6.58	$7.68	$7.07	$8.67	$8.14	$7.46	$9.74	$9.73	$9.21	$8.54
Total Capital	811	1,042	967	1,187	1,118	1,031	1,455	1,387	1,318	1,230
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1,106	-1,336	-1,288	-1,191	-1,117	-1,035	-1,428	-1,347	-1,282	-1,192
Capital Expenditures (CapEx)	6.05	4.85	2.79	5.85	2.07	2.24	2.15	4.79	3.88	5.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-328	-328	-354	-36	-38	-48	-46	-42	-55	-70
Debt-free Net Working Capital (DFNWC)	778	1,008	934	1,155	1,072	986	891	854	782	762
Net Working Capital (NWC)	778	1,008	934	1,155	1,072	986	891	854	782	762
Net Nonoperating Expense (NNE)	28	25	25	-13	20	27	19	17	21	24
Net Nonoperating Obligations (NNO)	-1,106	-1,336	-1,288	-1,191	-1,117	-1,035	-1,428	-1,347	-1,282	-1,192
Total Depreciation and Amortization (D&A)	1.45	2.66	2.19	-9.25	22	-42	-8.35	-8.12	23	2.62
Debt-free, Cash-free Net Working Capital to Revenue	-296.49%	-302.24%	-349.26%	-10.57%	-11.02%	-14.63%	-15.53%	-3,330.23%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	702.71%	929.72%	920.61%	336.54%	314.45%	298.35%	301.63%	67,391.48%	0.00%	0.00%
Net Working Capital to Revenue	702.71%	929.72%	920.61%	336.54%	314.45%	298.35%	301.63%	67,391.48%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.84)	($0.75)	($0.80)	$1.34	($0.72)	($0.88)	($0.68)	($0.59)	($0.63)	($0.67)
Adjusted Weighted Average Basic Shares Outstanding	123.47M	125.53M	136.52M	137.05M	137.64M	137.37M	149.40M	168.83M	169.46M	164.47M
Adjusted Diluted Earnings per Share	($0.84)	($0.75)	($0.80)	$1.30	($0.72)	($0.84)	($0.68)	($0.59)	($0.63)	($0.67)
Adjusted Weighted Average Diluted Shares Outstanding	123.47M	125.53M	136.52M	140.93M	137.64M	137.37M	149.40M	168.83M	169.46M	164.47M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	135.81M	136.68M	136.89M	137.42M	138.20M	139.16M	142.61M	143.17M	143.92M	145.22M
Normalized Net Operating Profit after Tax (NOPAT)	-75	-74	-85	119	-80	-93	-93	-82	-86	-91
Normalized NOPAT Margin	-2,114.08%	-717.11%	-240.66%	40.57%	-6,287.02%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-2,902.47%	-921.49%	-312.40%	62.35%	-7,841.59%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Denali Therapeutics' Financials

When does Denali Therapeutics's financial year end?

According to the most recent income statement we have on file, Denali Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Denali Therapeutics' net income changed over the last 8 years?

Denali Therapeutics' net income appears to be on an upward trend, with a most recent value of -$422.77 million in 2024, rising from -$86.65 million in 2016. The previous period was -$145.22 million in 2023. Find out what analysts predict for Denali Therapeutics in the coming months.

What is Denali Therapeutics's operating income?

Denali Therapeutics's total operating income in 2024 was -$487.34 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $487.34 million

How has Denali Therapeutics revenue changed over the last 8 years?

Over the last 8 years, Denali Therapeutics' total revenue changed from $0.00 in 2016 to $0.00 in 2024, a change of 0.0%.

How much debt does Denali Therapeutics have?

Denali Therapeutics' total liabilities were at $144.50 million at the end of 2024, a 17.5% increase from 2023, and a 590.5% increase since 2017.

How much cash does Denali Therapeutics have?

In the past 7 years, Denali Therapeutics' cash and equivalents has ranged from $77.12 million in 2018 to $507.14 million in 2020, and is currently $174.96 million as of their latest financial filing in 2024.

How has Denali Therapeutics' book value per share changed over the last 8 years?

Over the last 8 years, Denali Therapeutics' book value per share changed from 0.00 in 2016 to 8.54 in 2024, a change of 854.4%.

Related Companies

This page (NASDAQ:DNLI) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Financials

Frequently Asked Questions About Denali Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Denali Therapeutics (DNLI) Financials

Annual Income Statements for Denali Therapeutics

Quarterly Income Statements for Denali Therapeutics

Annual Cash Flow Statements for Denali Therapeutics

Quarterly Cash Flow Statements for Denali Therapeutics

Annual Balance Sheets for Denali Therapeutics

Quarterly Balance Sheets for Denali Therapeutics

Annual Metrics and Ratios for Denali Therapeutics

Quarterly Metrics and Ratios for Denali Therapeutics

Frequently Asked Questions About Denali Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools